Ravulizumab approved for children and adolescents

Ravulizumab approved for children and adolescents

Ravulizumab (trade name Ultomiris®) has been approved for the treatment of PNH in adults since July 2019, according to the manufacturer Alexion Pharmaceuticals, Inc. also the approval of the European Commission for use in children from 10 kg body weight and adolescents.